{"id":296007,"date":"2024-07-23T00:00:00","date_gmt":"2024-07-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?post_type=report&#038;p=296007"},"modified":"2026-03-31T10:29:09","modified_gmt":"2026-03-31T10:29:09","slug":"cutrim0016-2024-biopharma-ulcerative-colitis-current-treatment-current-treatment-physician-insights-ulcerative","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0016-2024-biopharma-ulcerative-colitis-current-treatment-current-treatment-physician-insights-ulcerative\/","title":{"rendered":"Ulcerative Colitis &#8211; Current Treatment &#8211; Current Treatment: Physician Insights \u2013 Ulcerative Colitis (EU5)"},"content":{"rendered":"<p>Many well-established therapies are available to treat ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>) in the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>. <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors (Janssen\u2019s Remicade, AbbVie\u2019s Humira), a <abbr title=\"cell adhesion molecule\">CAM<\/abbr> inhibitor (Takeda\u2019s Entyvio), and an <abbr title=\"interleukin\">IL<\/abbr>-12\/23 inhibitor (Janssen\u2019s Stelara) are the most widely used biologics for moderate to severe <abbr title=\"ulcerative colitis\">UC<\/abbr> and are entrenched as first-line biologics. In addition, several new therapies, including <abbr title=\"Janus-activated kinase\">JAK<\/abbr> inhibitors (Pfizer\u2019s Xeljanz, AbbVie\u2019s Rinvoq, and Alfasigma\u2019s Jyseleca), an <abbr title=\"interleukin\">IL<\/abbr>-23 inhibitor (Eli Lilly\u2019s Omvoh), <abbr title=\"sphingosine 1-phosphate\">S1P<\/abbr>-R modulators (<abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>\u2019s Zeposia and Pfizer\u2019s Velsipity), and biosimilars of infliximab and adalimumab have been approved for <abbr title=\"ulcerative colitis\">UC<\/abbr> in Europe in the past few years. The availability of agents from different drug classes and the launch of biosimilars not only expand treatment options but also influence physicians\u2019 prescribing behavior and thus the treatment landscape.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which drug classes are the patient-share leaders in each line of therapy? How are the various biological agents positioned in surveyed physicians\u2019 <abbr title=\"ulcerative colitis\">UC<\/abbr> treatment algorithm?<\/li>\n<li>What are the most influential drivers of treatment selection, and under which scenarios do\/will physicians prescribe Zeposia and Rinvoq?<\/li>\n<li>What are the common treatment scenarios before initiating each targeted therapy (i.e., Remicade, Humira, Simponi, Stelara, Entyvio, Rinvoq, Xeljanz, Jyseleca, Zeposia, biosimilar infliximab, and biosimilar adalimumab)?<\/li>\n<li>What factors drive therapy discontinuation and switching? What factors have\/will drive recent\/anticipated prescribing changes?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>France, Germany, Italy, Spain, and United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> 250 gastroenterologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded <a>in March 2024.<\/a><\/p>\n<p><strong>Key companies: <\/strong>Johnson &#038; Johnson Innovative Medicine, AbbVie, Takeda, Eli Lilly, Pfizer, <a>other<\/a>s<\/p>\n<p><strong>Key drugs: <\/strong>Humira, Remicade, Entyvio, Xeljanz, Stelara, Zeposia, Rinvoq, Jyseleca, adalimumab biosimilars, infliximab biosimilars<\/p>\n<p><strong>Product Description: <\/strong>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n","protected":false},"template":"","class_list":["post-296007","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastrointestinal","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-current-treatment","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296007\/revisions"}],"predecessor-version":[{"id":575935,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296007\/revisions\/575935"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}